Aflibercept biosimilar (Bioeq)

阿柏西普生物类似药 (Bioeq)

Report date: 2026/05/26 20:00:28

Base Information

Drug NameAflibercept biosimilar (Bioeq)
Drug Alias Nameaflibercept-mrbbAHZANTIVEBaiamaFYB-203
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[8] 
Global Approved IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[8] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/06/28
Country/TerritoryCzechiaBulgariaUnited States +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesFormycon AG
China Registration ClassN/A

Develop Information

Active CompaniesKlinge Biopharma GmbHFormycon AGCoherus Biosciences Inc +[4] 
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A